Hypertension in minority populations: New guidelines and emerging concepts

Advances in Chronic Kidney Disease

Volumn 22, Issue 2, 2015, Pages 145-153

  Rodriguez, Fátima ^a,b   Ferdinand, Keith C ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b University Heart and Vascular Institute   (United States)

Author keywords

Chronic kidney disease; Disparities; Guidelines; Hypertension; Racial ethnic minorities

Indexed keywords

AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; EPLERENONE; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL SUCCINATE; RAMIPRIL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VERAPAMIL;

AFRICAN AMERICAN; ANTIHYPERTENSIVE THERAPY; AWARENESS; BEHAVIOR CHANGE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); COMMUNITY CARE; DIETARY INTAKE; ELECTRONIC MEDICAL RECORD; ENVIRONMENTAL FACTOR; EVIDENCE BASED PRACTICE; EXERCISE; FOOD AVAILABILITY; GLOMERULUS FILTRATION RATE; HEALTH PROMOTION; HEREDITY; HISPANIC; HUMAN; HYPERTENSION; KIDNEY DENERVATION; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; MINORITY GROUP; MORBIDITY; POPULATION DISTRIBUTION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SOCIAL DETERMINANTS OF HEALTH; SODIUM RESTRICTION; WEIGHT REDUCTION; BLOOD PRESSURE; COMPLICATION; DISEASE MANAGEMENT; DRUG EFFECTS; ETHNOLOGY; HEALTH DISPARITY; RENAL INSUFFICIENCY, CHRONIC; SOCIOECONOMICS; UNITED STATES;

AFRICAN AMERICANS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE MANAGEMENT; HEALTH STATUS DISPARITIES; HISPANIC AMERICANS; HUMANS; HYPERTENSION; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84923851715     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.08.004     Document Type: Review

References (84)

1. Go A.S., Mozaffarian D., Roger V.L., et al. Executive summary: heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129(3):399-410.
2. Go A.S., Bauman M.A., Coleman King S.M., et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension 2014, 63(4):878-885.
3. Garimella P.S., Uhlig K. Current issues in the management and monitoring of hypertension in chronic kidney disease. Curr Opin Nephrol Hypertens 2013, 22(6):599-606.
4. Nwankwo T., Yoon S.S., Burt V., Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief 2013, (133):1-8.
5. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the Interheart Study): case-control study. Lancet 2004, 364(9438):937-952.
6. Hsu C.Y., McCulloch C.E., Darbinian J., Go A.S., Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005, 165(8):923-928.
7. Klag M.J., Whelton P.K., Randall B.L., et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996, 334(1):13-18.
8. Reynolds K., Gu D., Muntner P., et al. A population-based, prospective study of blood pressure and risk for end-stage renal disease in china. J Am Soc Nephrol 2007, 18(6):1928-1935.
9. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2013, 62(16):e147-e239.
10. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289(19):2560-2572.
11. James P.A., Oparil S., Carter B.L., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014, 311(5):507-520.
12. Bakris G.L., Ritz E. The message for world kidney day 2009: hypertension and kidney disease: a marriage that should be prevented. J Am Soc Hypertens 2009, 3(2):80-83.
13. Crews D.C., Plantinga L.C., Miller E.R., et al. Prevalence of chronic kidney disease in persons with undiagnosed or prehypertension in the United States. Hypertension 2010, 55(5):1102-1109.
14. Centers for Disease Control and Prevention (CDC). National chronic kidney disease fact sheet: general information and national estimates on chronic kidney disease in the United States. 2014. Available at: Accessed April, 19, 2014. http://www.cdc.gov/diabetes/pubs/factsheets/kidney.htm.
15. Peralta C.A., Weekley C.C., Li Y., Shlipak M.G. Occult chronic kidney disease among persons with hypertension in the united states: data from the National Health and Nutrition Surveys 1988-1994 and 1999-2002. J Hypertens 2013, 31(6):1196-1202.
16. Derose S.F., Rutkowski M.P., Crooks P.W., et al. Racial differences in estimated GFR decline, ESRD, and mortality in an integrated health system. Am J Kidney Dis 2013, 62(2):236-244.
17. Whittle J.C., Whelton P.K., Seidler A.J., Klag M.J. Does racial variation in risk factors explain black-white differences in the incidence of hypertensive end-stage renal disease?. Arch Intern Med 1991, 151(7):1359-1364.
18. Ferdinand K.C., Townsend R.R. Hypertension in the US black population: risk factors, complications, and potential impact of central aortic pressure on effective treatment. Cardiovasc Drugs Ther 2012, 26(2):157-165.
19. Joshi S., Gaynor J.J., Bayers S., et al. Disparities among blacks, Hispanics, and whites in time from starting dialysis to kidney transplant waitlisting. Transplantation 2013, 95(2):309-318.
20. Mensah G.A., Mokdad A.H., Ford E.S., Greenlund K.J., Croft J.B. State of disparities in cardiovascular health in the United States. Circulation 2005, 111(10):1233-1241.
21. Albert M.A., Torres J., Glynn R.J., Ridker P.M. Perspective on selected issues in cardiovascular disease research with a focus on black Americans. Circulation 2004, 110(2):e7-12.
22. Ferdinand K.C., Ferdinand D.P. Race-based therapy for hypertension: possible benefits and potential pitfalls. Expert Rev Cardiovasc Ther 2008, 6(10):1357-1366.
23. Rahman M., Douglas J.G., Wright J.T. Pathophysiology and treatment implications of hypertension in the African-American population. Endocrinol Metab Clin North Am 1997, 26(1):125-144.
24. Howard G., Lackland D.T., Kleindorfer D.O., et al. Racial differences in the impact of elevated systolic blood pressure on stroke risk. JAMA Intern Med 2013, 173(1):46-51.
25. Borrell L.N., Menendez B.S., Joseph S.P. Racial/ethnic disparities on self-reported hypertension in New York City: examining disparities among Hispanic subgroups. Ethn Dis 2011, 21(4):429-436.
26. Guzman N.J. Epidemiology and management of hypertension in the Hispanic population: a review of the available literature. Am J Cardiovasc Drugs 2012, 12(3):165-178.
27. Sorlie P.D., Allison M.A., Aviles-Santa M.L., et al. Prevalence of hypertension, awareness, treatment, and control in the Hispanic Community Health Study/Study of Latinos. Am J Hypertens 2014, 27(6):793-800.
28. Lora C.M., Gordon E.J., Sharp L.K., et al. Progression of CKD in Hispanics: potential roles of health literacy, acculturation, and social support. Am J Kidney Dis 2011, 58(2):282-290.
29. Lora C.M., Daviglus M.L., Kusek J.W., et al. Chronic kidney disease in United States Hispanics: a growing public health problem. Ethn Dis 2009, 19(4):466-472.
30. Bryson C.L., Ross H.J., Boyko E.J., Young B.A. Racial and ethnic variations in albuminuria in the US Third National Health and Nutrition Examination Survey (NHANES III) population: associations with diabetes and level of CKD. Am J Kidney Dis 2006, 48(5):720-726.
31. Fischer M.J., Go A.S., Lora C.M., et al. CKD in Hispanics: baseline characteristics from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC studies. Am J Kidney Dis 2011, 58(2):214-227.
32. Yi S., Elfassy T., Gupta L., Myers C., Kerker B. Nativity, language spoken at home, length of time in the united states, and race/ethnicity: associations with self-reported hypertension. Am J Hypertens 2014, 27(2):237-244.
33. Rodriguez F., Hicks L.S., Lopez L. Association of acculturation and country of origin with self-reported hypertension and diabetes in a heterogeneous Hispanic population. BMC Public Health 2012, 12:768.
34. Moran A., Diez Roux A.V., Jackson S.A., et al. Acculturation is associated with hypertension in a multiethnic sample. Am J Hypertens 2007, 20(4):354-363.
35. Day E.C., Li Y., Diez-Roux A., et al. Associations of acculturation and kidney dysfunction among Hispanics and Chinese from the Multi-ethnic Study of Atherosclerosis (MESA). Nephrol Dial Transplant 2011, 26(6):1909-1916.
36. Pabon-Nau L.P., Cohen A., Meigs J.B., Grant R.W. Hypertension and diabetes prevalence among U.S. Hispanics by country of origin: the National Health Interview Survey 2000-2005. J Gen Intern Med 2010, 25(8):847-852.
37. Daviglus M.L., Talavera G.A., Aviles-Santa M.L., et al. Prevalence of major cardiovascular risk factors and cardiovascular diseases among Hispanic/Latino individuals of diverse backgrounds in the United States. JAMA 2012, 308(17):1775-1784.
38. Aoki Y., Chong Y., Carroll M.D. Hypertension, abnormal cholesterol, and high body mass index among non-Hispanic Asian adults: United states 2011-2012. National Center for Health Statistics Data Brief 2014, (140):1-8.
39. Ferdinand K.C. Hypertension in minority populations. J Clin Hypertens (Greenwich) 2006, 8(5):365-368.
40. Nesbitt S.D. Hypertension in black patients: special issues and considerations. Curr Hypertens Rep 2005, 7(4):244-248.
41. Gadegbeku C.A., Lea J.P., Jamerson K.A. Update on disparities in the pathophysiology and management of hypertension: focus on African Americans. Med Clin North Am 2005, 89(5):921-933. 930.
42. Forman J.P., Scott J.B., Ng K., et al. Effect of vitamin D supplementation on blood pressure in blacks. Hypertension 2013, 61(4):779-785.
43. Adefurin A., Ghimire L.V., Kohli U., et al. Blacks have a greater sensitivity to alpha1-adrenoceptor-mediated venoconstriction compared with whites. Hypertension 2013, 61(4):915-920.
44. Ogedegbe G., Spruill T.M., Sarpong D.F., et al. Correlates of isolated nocturnal hypertension and target organ damage in a population-based cohort of African Americans: the Jackson Heart Study. Am J Hypertens 2013, 26(8):1011-1016.
45. Parsa A., Kao W.H., Xie D., et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013, 369(23):2183-2196.
46. Kershaw K.N., Diez Roux A.V., Carnethon M., et al. Geographic variation in hypertension prevalence among blacks and whites: the Multi-ethnic Study of Atherosclerosis. Am J Hypertens 2010, 23(1):46-53.
47. Plantinga L., Howard V.J., Judd S., et al. Association of duration of residence in the southeastern united states with chronic kidney disease may differ by race: the reasons for geographic and racial differences in Stroke (regards) Cohort study. Int J Health Geogr 2013, 12:17.
48. Rodriguez C.J., Diez-Roux A.V., Moran A., et al. Left ventricular mass and ventricular remodeling among Hispanic subgroups compared with non-Hispanic blacks and whites: MESA (Multi-ethnic Study of Atherosclerosis). J Am Coll Cardiol 2010, 55(3):234-242.
49. Palmer Alves T., Lewis J. Racial differences in chronic kidney disease (CKD) and end-stage renal disease (ESRD) in the United States: a social and economic dilemma. Clin Nephrol 2010, 74(suppl 1):S72-S77.
50. Eamranond P.P., Legedza A.T., Diez-Roux A.V., et al. Association between language and risk factor levels among Hispanic adults with hypertension, hypercholesterolemia, or diabetes. Am Heart J 2009, 157(1):53-59.
51. Eamranond P.P., Wee C.C., Legedza A.T., Marcantonio E.R., Leveille S.G. Acculturation and cardiovascular risk factor control among Hispanic adults in the United States. Public Health Rep 2009, 124(6):818-824.
52. Traylor A.H., Schmittdiel J.A., Uratsu C.S., Mangione C.M., Subramanian U. Adherence to cardiovascular disease medications: does patient-provider race/ethnicity and language concordance matter?. J Gen Intern Med 2010, 25(11):1172-1177.
53. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985, 14(1):32-38.
54. Weber M.A., Schiffrin E.L., White W.B., et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) 2014, 16(1):14-26.
55. Frieden T.R., Berwick D.M. The "million hearts" initiative-preventing heart attacks and strokes. N Engl J Med 2011, 365(13):e27.
56. Victor R.G., Ravenell J.E., Freeman A., et al. Effectiveness of a barber-based intervention for improving hypertension control in black men: the barber-1 study: a cluster randomized trial. Arch Intern Med 2011, 171(4):342-350.
57. Jaffe M.G., Lee G.A., Young J.D., Sidney S., Go A.S. Improved blood pressure control associated with a Large-Scale Hypertension Program. JAMA 2013, 310(7):699-705.
58. Fletcher R.D., Amdur R.L., Kolodner R., et al. Blood pressure control among us veterans: a large multiyear analysis of blood pressure data from the Veterans Administration health data repository. Circulation 2012, 125(20):2462-2468.
59. Sacks F.M., Svetkey L.P., Vollmer W.M., et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. Dash-Sodium Collaborative Research Group. N Engl J Med 2001, 344(1):3-10.
60. Eckel R.H., Jakicic J.M., Ard J.D., et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2014, 29(25 suppl 2):S76-S99.
61. Guide to Community Preventive Services. Cardiovascular disease prevention and control: team-based care to improve blood pressure control. Available at: Accessed April, 19, 2014. http://www.Thecommunityguide.Org/cvd/teambasedcare.Html.
62. Sharma S., McFann K., Chonchol M., de Boer I.H., Kendrick J. Association between dietary sodium and potassium intake with chronic kidney disease in us adults: a cross-sectional study. Am J Nephrol 2013, 37(6):526-533.
63. Ninomiya T., Perkovic V., Turnbull F., et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ 2013, 347:f5680.
64. Wright J.T., Fine L.J., Lackland D.T., Ogedegbe G., Dennison Himmelfarb C.R. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med 2014, 160(7):499-503.
65. Saunders E., Weir M.R., Kong B.W., et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990, 150(8):1707-1713.
66. Materson B.J., Reda D.J., Cushman W.C., et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993, 328(13):914-921.
67. Flack J.M., Sica D.A., Bakris G., et al. Management of high blood pressure in blacks: an update of the international society on hypertension in blacks consensus statement. Hypertension 2010, 56(5):780-800.
68. Upadhyay A., Earley A., Haynes S.M., Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 2011, 154(8):541-548.
69. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association professional education committee of the council for high blood pressure research. Circulation 2008, 117(25):e510-526.
70. Khosla N., Kalaitzidis R., Bakris G.L. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009, 30(5):418-424.
71. Fried L.F., Emanuele N., Zhang J.H., et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013, 369(20):1892-1903.
72. Mann J.F., Schmieder R.E., McQueen M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the Ontarget Study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372(9638):547-553.
73. Parving H.H., Brenner B.M., McMurray J.J., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012, 367(23):2204-2213.
74. Wright J.T., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288(19):2421-2431.
75. Wright J.T., Dunn J.K., Cutler J.A., et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005, 293(13):1595-1608.
76. Julius S., Alderman M.H., Beevers G., et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the life study. J Am Coll Cardiol 2004, 43(6):1047-1055.
77. Margolis K.L., Piller L.B., Ford C.E., et al. Blood pressure control in Hispanics in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack trial. Hypertension 2007, 50(5):854-861.
78. Cooper-DeHoff R.M., Aranda J.M., Gaxiola E., et al. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients-findings from the International Verapamil SR/Trandolapril Study (INVEST). Am Heart J 2006, 151(5):1072-1079.
79. Parving H.H., Lehnert H., Brochner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345(12):870-878.
80. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345(12):861-869.
81. Hsu T.W., Liu J.S., Hung S.C., et al. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern Med 2014, 174(3):347-354.
82. Ott C., Mahfoud F., Schmid A., et al. Renal denervation in moderate treatment-resistant hypertension. J Am Coll Cardiol 2013, 62(20):1880-1886.
83. Esler M.D., Krum H., Sobotka P.A., et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet 2010, 376(9756):1903-1909.
84. Bhatt D.L., Kandzari D.E., O'Neill W.W., et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014, 370(15):1393-1401.